Axogen/$AXGN

13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1Y5YMAX

About Axogen

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Ticker

$AXGN
Primary listing

Industry

Health Care Equipment & Supplies

Employees

452

ISIN

US05463X1063

Axogen Metrics

BasicAdvanced
$498M
-
-$0.16
1.19
-

What the Analysts think about Axogen

Analyst ratings (Buy, Hold, Sell) for Axogen stock.

Bulls say / Bears say

Axogen's stock price reached a 52-week high of $19.25 in February 2025, reflecting strong investor confidence and an 80.77% increase over the past year. (Investing.com)
The company reported Q4 2024 earnings with an EPS of $0.07, surpassing analyst expectations of $0.03, and revenue of $49.4 million, exceeding the anticipated $47.58 million. (Investing.com)
Axogen has projected a revenue growth of 15-17% for 2025, indicating strong future performance expectations. (Investing.com)
Cantor Fitzgerald reduced its FY2025 earnings per share estimate for Axogen from $0.07 to $0.02, suggesting potential challenges in meeting previous earnings expectations. (Defense World)
Despite revenue growth, Axogen's operating expenses increased to $36.8 million in Q3 2024, which could impact profitability. (Investing.com)
The company's gross margin decreased to 74.9% in Q3 2024 from 76.8% year-over-year, indicating potential pressure on profit margins. (Investing.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jul 2025.

Axogen Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Axogen Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $AXGN

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs